ATTAIN-2 (NCT05872620) was a Phase III, 72-week, randomized, double-blind, placebo-controlled trial comparing the efficacy and safety of various doses of orforglipron with placebo in adults with obesity or overweight and type 2 diabetes
About 57 percent lost at least 20 percent of their body weight
RT and its GSH adduct (RT-GSH) shows fluorescence maxima at 487 and 562 nm with excitation wavelengths at 405 and 488 nm, respectively (Fig
Some researchers have explored whether medium-chain triglycerides such as C10 may help support muscle metabolism through nitrogen-sparing and anabolic signaling pathways, but this area is still being studied and no supplement should replace the foundational strategies of protein and resistance training
Anti-inflammatory effects of lutein in retinal ischemic/hypoxic injury: In vivo and in vitro studies
Clinical trial data for GLP-1 medicines, including Ozempic, Mounjaro, Wegovy/Wegovy HD, Zepbound, and Foundayo, were reviewed to compare reported weight-loss results, FDA-approved uses, and study limitations